Literature DB >> 30780103

The role of microRNA-16 in the pathogenesis of autoimmune diseases: A comprehensive review.

Lan Yan1, Mingge Liang1, Xiaoqiang Hou2, Yiwen Zhang1, Haoran Zhang1, Zhe Guo1, Ji Jinyu1, Zhitao Feng3, Zhigang Mei4.   

Abstract

MicroRNAs (miRNAs) are a class of small noncoding RNAs that are only 21-25 nt long. Many studies have shown that miRNA dysfunction is closely related to the occurrence and development of diseases. By combining with the 3' noncoding region of target gene mRNA, miRNAs can mediate the degradation or translation inhibition of mRNA and exert a powerful regulation effect on gene expression at the posttranscriptional level, mainly inhibiting the translation or degradation of targets. Therefore, they are a class of molecules that play a negative regulatory role. Current studies have found that miR-16 is closely related to the occurrence of several autoimmune diseases. Studies have reported that miR-16 participates in the occurrence and development of rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, inflammatory bowel disease, autoimmune thyroid disease, juvenile idiopathic arthritis, primary Sjogren's syndrome and other autoimmune diseases by regulating the expression of cytokines such as TNF-α, IL-8, IL-6, and IL-4; regulating activin A receptor (ACVR), growth differentiation factor-5 (GDF-5) and adenosine A2a receptor (A2AR) expression; affecting the proliferation, differentiation of Th17 cells and Treg cells; and regulating the balance between the cells. In this review, emphasis will be placed on the recent progress in characterizing the roles of miR-16 in these autoimmune diseases.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Autoimmune; Autoimmune diseases; miR-16

Mesh:

Substances:

Year:  2019        PMID: 30780103     DOI: 10.1016/j.biopha.2019.01.044

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

1.  hnRNPH1-MTR4 complex-mediated regulation of NEAT1v2 stability is critical for IL8 expression.

Authors:  Tanzina Tanu; Kenzui Taniue; Katsutoshi Imamura; Rena Onoguchi-Mizutani; Han Han; Torben Heick Jensen; Nobuyoshi Akimitsu
Journal:  RNA Biol       Date:  2021-09-01       Impact factor: 4.766

2.  miR-148a-3p facilitates osteogenic differentiation of fibroblasts in ankylosing spondylitis by activating the Wnt pathway and targeting DKK1.

Authors:  Wenbo Sheng; Haitao Jiang; Hantao Yuan; Sibo Li
Journal:  Exp Ther Med       Date:  2022-04-01       Impact factor: 2.751

3.  Determining Immune and miRNA Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types.

Authors:  Lydia J Atherton; Patricia A Jorquera; Abhijeet A Bakre; Ralph A Tripp
Journal:  Front Immunol       Date:  2019-10-09       Impact factor: 7.561

4.  Analysis of ROQUIN, Tristetraprolin (TTP), and BDNF/miR-16/TTP regulatory axis in late onset Alzheimer's disease.

Authors:  Mohammad Reza Asadi; Mahnaz Talebi; Jalal Gharesouran; Hani Sabaie; Abbas Jalaiei; Shahram Arsang-Jang; Mohammad Taheri; Arezou Sayad; Maryam Rezazadeh
Journal:  Front Aging Neurosci       Date:  2022-08-09       Impact factor: 5.702

5.  High-glucose induced toxicity in HK-2 cells can be alleviated by inhibition of miRNA-320c.

Authors:  Yan Sun; Hai Qu; Qi Song; Yifan Shen; Lijuan Wang; Xiaohong Niu
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

6.  MicroRNAs: Potential mediators between particulate matter 2.5 and Th17/Treg immune disorder in primary membranous nephropathy.

Authors:  Xiaoshan Zhou; Haoran Dai; Hanxue Jiang; Hongliang Rui; Wenbin Liu; Zhaocheng Dong; Na Zhang; Qihan Zhao; Zhendong Feng; Yuehong Hu; Fanyu Hou; Yang Zheng; Baoli Liu
Journal:  Front Pharmacol       Date:  2022-09-21       Impact factor: 5.988

7.  Differential long non-coding RNA expression profile and function analysis in primary Sjogren's syndrome.

Authors:  Xiaochan Chen; Qi Cheng; Yan Du; Lei Liu; Huaxiang Wu
Journal:  BMC Immunol       Date:  2021-07-20       Impact factor: 3.615

Review 8.  Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease.

Authors:  Bahez Gareb; Antonius T Otten; Henderik W Frijlink; Gerard Dijkstra; Jos G W Kosterink
Journal:  Pharmaceutics       Date:  2020-06-11       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.